力源信息(300184.SZ):公司目前與英偉達沒有合作
格隆匯6月1日丨有投資者在投資者互動平台向力源信息(300184.SZ)提問,“請問董祕,公司有沒有代理英偉達產品。代理的產品每年的營收額大概是多少?公司目前的芯片研發進度和生產能力,到年底會不會實現大幅增長”
公司回覆稱,公司目前與英偉達沒有合作。公司營收數據可查閲各年披露的年度報吿。 公司已推出微處理器MCU、小容量存儲芯片EEPROM、功率器件SJ-MOSFET三大系列產品,並不斷推出新的型號及進行老產品迭代。截至目前,MCU共推出9個系列26個型號產品,其中7個系列24個型號已經量產。2022年度、2023年一季度公司自研芯片銷售收入分別為3373萬元、1023萬元。公司今年將繼續加大自研及銷售力度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.